Soleno Therapeutics Inc (NASDAQ: SLNO) open the trading on Wednesday, with great promise as it jumped 0.61% to $49.14, before settling in for the price of $48.84 at the close. Taking a more long-term approach, SLNO posted a 52-week range of $41.50-$90.32.
The company of the Healthcare sector’s yearbook sales growth during the past 5- year span was recorded 20.19%. Meanwhile, its Annual Earning per share during the time was 20.19%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 104.29%. This publicly-traded company’s shares outstanding now amounts to $53.70 million, simultaneously with a float of $49.27 million. The organization now has a market capitalization sitting at $2.64 billion. At the time of writing, stock’s 50-day Moving Average stood at $54.07, while the 200-day Moving Average is $67.29.
Soleno Therapeutics Inc (SLNO) Ownership Facts and Figures
Sometimes it helps to make our mind if we keep our tabs on how bigger investors are working with the stock of the Biotechnology industry. Soleno Therapeutics Inc’s current insider ownership accounts for 8.27%, in contrast to 117.16% institutional ownership. Preceding that transaction, on Jul 01 ’25, Company’s insider sold 3,830 for 82.76, making the whole transaction’s value amount to 316,971. This particular insider is now the holder of 13,206 in total.
Soleno Therapeutics Inc (SLNO) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.68 per share during the current fiscal year.
Soleno Therapeutics Inc’s EPS increase for this current 12-month fiscal period is 104.29% and is forecasted to reach 4.11 in the upcoming year.
Soleno Therapeutics Inc (NASDAQ: SLNO) Trading Performance Indicators
Let’s observe the current performance indicators for Soleno Therapeutics Inc (SLNO). It’s Quick Ratio in the last reported quarter now stands at 15.88. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 26.75.
In the same vein, SLNO’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -1.84, a figure that is expected to reach 0.62 in the next quarter, and analysts are predicting that it will be 4.11 at the market close of one year from today.
Technical Analysis of Soleno Therapeutics Inc (SLNO)
[Soleno Therapeutics Inc, SLNO] recent stats showed that its last 5-days Average volume was poorer than the volume it posted in the year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 28.76% While, its Average True Range was 47.33.
Raw Stochastic average of Soleno Therapeutics Inc (SLNO) in the period of the previous 100 days is set at 16.18%, which indicates a major fall in contrast to 25.22% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 2.40 that was lower than 3.49 volatility it exhibited in the past 100-days period.
